Common symptoms
- •Hot flushes, night sweats
- •Vaginal dryness, urinary changes
- •Sleep disruption
- •Mood changes, brain fog
- •Bone density loss (silent)
- •Cardiovascular risk shifts
What drives it
- •Ovarian estrogen and progesterone production ends
Testing approach
Postmenopausal testing focuses on long-term protection — bone, metabolic and cardiovascular markers — alongside hormone levels to guide HRT decisions.
What to do next
- ✓Strength train and prioritise protein for bone and muscle
- ✓Address sleep, vasomotor symptoms and vaginal/urinary health early
- ✓Track metabolic and cardiovascular markers annually
Frequently asked
Average age globally is 51. Anything before 40 is premature menopause; 40–45 is early menopause — both deserve specialist input because of long-term bone and heart implications.
Yes — to guide HRT dosing and to track bone, metabolic and cardiovascular risk that quietly increase once estrogen is low.
No, but it identifies the women most at risk so a DEXA scan can be timed appropriately.
Vasomotor symptoms (hot flushes, night sweats) last a median of 7 years; about a third of women have them for 10+ years. Genitourinary symptoms are permanent without treatment.
For most women starting within 10 years of menopause, HRT benefits outweigh risks. Starting later or with cardiovascular disease present needs a specialist conversation.
Spontaneous conception is rare but documented up to about a year after the last period. Contraception is recommended for 12 months after periods stop (or 24 if menopause was before 50).
Perimenopause is the transition — fluctuating hormones, irregular cycles. Menopause is one day, the 12-month anniversary of your last period. Everything after is postmenopause.
References
- NICE — Menopause guideline (NG23)— Menopause diagnosis and management
- British Menopause Society (BMS)— HRT safety, vasomotor symptoms and bone protection
- Jean Hailes for Women's Health— Post-menopause long-term health
- RANZCOG — Menopause position statement— HRT and cardiovascular/bone risk in ANZ women
- Endocrine Society — Hormone Therapy guidelines— Evidence on hormonal interventions in menopause
References are provided for educational context only. Her Form is not affiliated with these organisations. Always interpret results with a qualified healthcare professional.